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Abstract
Alkylating agents comprise a major class of front-line cancer chemotherapeutic compounds, and while these agents
effectively kill tumor cells, they also damage healthy tissues. Although base excision repair (BER) is essential in repairing
DNA alkylation damage, under certain conditions, initiation of BER can be detrimental. Here we illustrate that the
alkyladenine DNA glycosylase (AAG) mediates alkylation-induced tissue damage and whole-animal lethality following
exposure to alkylating agents. Aag-dependent tissue damage, as observed in cerebellar granule cells, splenocytes,
thymocytes, bone marrow cells, pancreatic b-cells, and retinal photoreceptor cells, was detected in wild-type mice,
exacerbated in Aag transgenic mice, and completely suppressed in Aag2/2 mice. Additional genetic experiments dissected
the effects of modulating both BER and Parp1 on alkylation sensitivity in mice and determined that Aag acts upstream of
Parp1 in alkylation-induced tissue damage; in fact, cytotoxicity in WT and Aag transgenic mice was abrogated in the
absence of Parp1. These results provide in vivo evidence that Aag-initiated BER may play a critical role in determining the
side-effects of alkylating agent chemotherapies and that Parp1 plays a crucial role in Aag-mediated tissue damage.
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Introduction
DNA damage continually arises from environmental agents and
reactive byproducts of normal cellular function. Moreover, DNA
damage is deliberately induced during the course of cancer
chemotherapy. Such damage can result in cell death, mutagenesis,
and genetic instability thus promoting tissue degeneration, aging,
cancer, and sometimes death. DNA repair pathways have evolved
to cope with recurring DNA damage, providing protection against
carcinogenesis, neurodegeneration, and premature aging [1–5].
Understandably, loss of function mutations have been extensively
studied, whereas genetic variants that result in increased DNA
repair activity have not received the same attention, primarily
because decreased DNA repair is thought to be more relevant for
increased cancer risk. While this concept is accurate for many
DNA repair proteins [1–3], a growing body of evidence suggests
that increased levels of certain DNA repair enzymes can result in
loss of coordination between the enzymatic steps within a
particular DNA repair pathway; such loss of coordination can
negatively impact cellular homeostasis [6–9].
The base excision repair (BER) pathway acts on a wide range of
DNA base lesions including alkylated, oxidized, and deaminated
bases, as well as abasic (AP) sites and DNA single-strand breaks
(SSBs) (reviewed in [6,10]). In its most simplified form, BER is
coordinated into 4 main steps (Figure 1A). DNA glycosylases
recognize and excise specific base lesions by cleaving the N-
glycosyl bond, forming an AP site. AP endonuclease (APE1) then
hydrolyzes the phosphodiester backbone, generating a single-
stranded DNA break (SSB) with 39OH and 59deoxyribose-5-
phosphate (59dRP) termini. DNA polymerase b (Pol b) contains a
lyase domain that removes the 59dRP terminus and a polymerase
domain that replaces the missing nucleotide. Finally, BER is
completed upon ligation of the nick by DNA Ligase I or the
Xrcc1/Ligase IIIa complex (Figure 1A).
Importantly, numerous BER intermediates (AP sites, 59dRP
termini, and SSBs) are toxic if allowed to accumulate rather than
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being efficiently shuttled through the downstream BER steps
(Figure 1A). Both SSBs and AP sites exert their toxicity as a
function of blocking transcription and replication [11]. Further,
large numbers of SSBs can indirectly induce toxicity through the
hyperactivation of poly(ADP-ribose) polymerase 1 (Parp1) [12]
(Figure 1B). AP sites can also be mutagenic; although translesion
DNA polymerases can prevent toxicity by bypassing AP sites, such
bypass can generate point mutations [13–17]. The 59dRP
intermediate is particularly toxic in mouse embryonic fibroblasts
(MEFs) and the alkylation sensitivity of Polb deficient MEFs is
almost completely suppressed upon expression of the Pol b 59dRP
lyase domain [18]. The toxic nature of BER intermediates
underscores why this pathway must be tightly regulated and why
alterations in any step of the pathway, without compensatory
changes in upstream/downstream steps, can result in the
accumulation of toxic intermediates. A clear example of this was
illustrated by the fact that hypersensitivity to the alkylating agent
methyl methanesulfonate (MMS) in Polb2/2 MEFs is completely
suppressed if BER is not initiated by the alkyladenine DNA
glycosylase (AAG, also known as MPG, ANPG) [19]. Therefore,
although BER is essential for the repair of many different types of
DNA damage, it must be carefully regulated to avoid the
accumulation of toxic BER intermediates.
Aag has a wide substrate specificity, excising numerous
structurally-diverse lesions, some of which are innocuous (e.g. 7-
methylguanine), while others can be replication-blocking and
cytotoxic (e.g. 3-methyladenine) [20–27]. The absence of Aag
should therefore result in unrepaired alkylated DNA bases that are
replication-blocking lesions, thus increasing cytotoxicity; strikingly,
the converse is seen in certain Aag deficient tissues. Aag2/2 bone
marrow cells are MMS resistant in ex vivo survival assays [28], and
Aag2/2 retinal photoreceptor cells are remarkably refractory to
MMS-induced death [29]. Thus, when BER is not initiated,
MMS-induced cytotoxicity is avoided, presumably by preventing
the accumulation of toxic intermediates, and by translesion DNA
synthesis (TLS) bypassing lesions in replicating cells (Figure 1B).
The multi-functional protein, Parp1, mediates several cellular
processes including stress responses, transcriptional regulation, and
DNA SSB repair and BER [30–32]. Parp1’s role as a molecular
sensor of SSBs is well established; upon binding DNA breaks,
Parp1 adds poly(ADP-ribose) (PAR) polymers to numerous
nuclear proteins including itself, DNA polymerases, DNA ligases,
transcription factors, and histones [31,33]. Parp1 automodification
facilitates BER by recruiting the scaffold protein XRCC1 that in
turn facilitates the formation of a BER repair complex comprising
APE1, DNA Pol b, and DNA ligase III [34–36]. Further,
PARylation of histones, Parp1, and chromatin remodeling
enzymes relaxes chromatin allowing DNA repair proteins access
to damaged DNA [37–39]. Importantly, Parp1 is also a cell death
mediator [12]; upon excessive levels of DNA damage, Parp1
hyperactivation vastly increases NAD+ consumption resulting in
depletion of both NAD+ and ATP, such that cells succumb to
bioenergetic failure (Figure 1B). Independent of NAD+/ATP
depletion, the PAR polymer can also stimulate cell death by
facilitating translocation of apoptosis inducing factor (AIF) from
mitochondria to the nucleus, resulting in chromatin condensation,
caspase-independent DNA degradation, and ultimately cell death
[12,40,41]. While the various roles of Parp1 in programmed
necrosis are still being elucidated, it is quite clear that Parp1 is a
central player.
Imbalanced BER can arise either by increased DNA glycosylase
activity, or by a decrease in any downstream BER step (reviewed
in [6]). For example, decreased Pol b activity, as observed in the
PolbY265C/Y265C knock-in mice, results in an accumulation of BER
Figure 1. Cellular processing and repair of DNA base lesions in
DNA. (A) DNA base lesions induced by SN1 or SN2 alkylating agent are
recognized and excised by the DNA glycosylase, Aag, to generate an AP
site. The base excision repair (BER) pathway continues when an AP
endonuclease cleaves the DNA backbone to generate 39 hydroxyl and
59 deoxyribose phosphate (59dRP) termini. Polymerase b removes the
59dRP species, and inserts the missing DNA bases; DNA ligase
completes BER by sealing the nicked DNA. (B) Error-prone translesion
(TLS) polymerases can assist in the tolerance or bypass of base lesions
and AP sites. Parp1 has an important role in regulating the response to
DNA damage. During times of moderate DNA damage, Parp1 activation
facilitates BER. Upon high levels of DNA damage, Parp1 undergoes
hyperactivation; cells consequently suffer NAD+/ATP depletion, trigger-
ing cell death.
doi:10.1371/journal.pgen.1003413.g001
Author Summary
Alkylating agents are genotoxic chemicals that induce
both toxic and mutagenic DNA damage through addition
of an alkyl group to DNA. Alkylating agents are routinely
and successfully used as chemotherapeutic therapies for
cancer patients, with one major disadvantage being the
significant toxicity induced in non-tumor tissues. Accord-
ingly, identifying factors that modify susceptibility to
alkylation-induced toxicity will provide valuable informa-
tion in designing cancer therapeutic regimens. This study
used mouse genetic experiments to investigate whether
proteins important in the base excision repair pathway
modulate susceptibility to alkylating agents. In addition to
whole-animal toxicity at high doses, treatment of mice
with alkylating agents resulted in severe damage to
numerous tissues including the cerebellum, retina, bone
marrow, spleen, thymus, and the pancreas. We illustrate
that the DNA glycosylase Aag can actually confer, rather
than prevent, alkylation sensitivity at both the whole-
animal and tissue level; i.e., Aag transgenic animals are
more susceptible than wild type, whereas Aag-deficient
animals are less susceptible than wild type to alkylation-
induced toxicity. Further genetic experiments show that
the Aag-mediated alkylation sensitivity is dependent on
Parp1. Given that we observe a wide range of human AAG
expression among healthy individuals, this and other base
excision repair proteins may be important factors modu-
lating alkylation susceptibility.
Aag and Parp1 Confer Alkylation Sensitivity in Mice
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intermediates, causing severe physiological consequences [42].
Interestingly, recent studies generated imbalanced BER by both
increasing Aag activity and eliminating Pol b activity; such cells
displayed enhanced alkylation sensitivity [43,44]. Although BER
imbalance increases alkylation sensitivity in cultured cells, the
effects of BER imbalance on in vivo alkylation sensitivity have not
yet been extensively studied. Using transgenic mice exhibiting
modestly increased Aag activity, we investigated the effects of
imbalanced BER in many tissues. We show that AagTg mice
exhibit dramatic alkylation sensitivity, at both the tissue and the
whole-body level, consistent with imbalanced BER leading to the
accumulation of toxic intermediates. Moreover, we show that
Parp1 deficiency prevents alkylation-induced damage in numerous
tissues, indicating that the Aag-dependent alkylation sensitivity
observed in vivo occurs in a Parp1-dependent manner.
Results
Generation of AagTg mice to model BER imbalance in
vivo
BER modulation has recently attracted attention as a way to
potentiate alkylation sensitivity [6,30,44–48]. To investigate the
consequences of imbalanced BER in vivo, we generated Aag
transgenic (AagTg) mice; Table S1 displays the Aag activity levels in
three transgenic founder (Fo) lines. Fo line 243 exhibits increased
Aag activity in all tissues examined, with a ,2–9-fold increase
compared to WT levels (Table S1 and Figure S1A). Fo line 8756
displays negligible increases in Aag activity in every tissue except
the cerebellum. Finally, Aag activity in Fo line 943 tissues falls in-
between, with 1.5–4-fold increases compared to WT levels. To
add context to the range of Aag activities in our AagTg mice, we
examined human AAG activity in peripheral blood mononuclear
cells (PBMC) of healthy individuals. We observe .10-fold
variation in AAG activity in this healthy population, as measured
by excision of 19N6 ethenoadenine (eA) bases from DNA (Figure 2);
eA represents one of AAG’s many substrates [23,26]. This wide
range of AAG activity among healthy individuals is similar to that
recently reported [7].
Imbalanced BER increases whole-body sensitivity to
alkylating agents
AagTg mice are viable and fertile, and an aging study revealed
no apparent differences in lifespan or tumor incidence between
WT, Aag2/2 and AagTg Fo line 243 (Figure S1B and data not
shown). Although increased Aag activity in vivo does not
significantly alter longevity or spontaneous tumor incidence, it
does profoundly affect how mice respond to DNA damage. Similar
to our previous published findings, WT and Aag2/2 mice display
the same approximate LD50 for MMS (150 mg/kg) (Table 1) [28].
However, AagTg Fo 243, with a 2–9-fold increase in Aag activity,
exhibits a dramatic increase in MMS sensitivity (Table 1). Mice
with intermediate Aag levels (AagTg Fo 943) have an intermediate
LD50, and AagTg Fo 8756, with negligible Aag activity in most
tissues, exhibits the same MMS LD50 as WT and Aag
2/2 mice
(Table 1). Therefore, increased Aag activity sensitizes animals to
MMS-induced whole-body lethality.
We next determined whether Aag activity affects the approx-
imate LD50 for other genotoxic agents: N-methyl-N-nitrosourea
(MNU), azoxymethane (AOM), mitomycin C (MMC), and
chloroacetaldehyde (CAA). Table 2 illustrates that while the
AagTg Fo 243 mice show dramatically increased whole-body
sensitivity to three different methylating agents (MMS, MNU and
AOM), they were not sensitized to non-methylating genotoxic
agents (MMC and CAA). Thus, Aag activity dictates sensitivity to
both SN1 (MNU and AOM) and SN2 methylating agents (MMS),
but not to the other genotoxic agents examined. Since the
increased Aag activity in AagTg Fo 243 mice falls within the range
observed in PBMCs of a healthy human population, this founder
line was chosen to further examine the consequences of BER
imbalance, and are henceforth referred to as AagTg mice.
AagTg mice exhibit increased MMS cytotoxicity in
numerous, but not all, tissues
Histopathological analysis was performed on tissues harvested
from WT, Aag2/2, and AagTg mice 24 h following MMS
Figure 2. Human peripheral blood mononuclear cells (PBMCs)
exhibit a wide range in AAG activity. An in vitro glycosylase assay
determined AAG activity in PBMCs isolated from 80 healthy individuals.
doi:10.1371/journal.pgen.1003413.g002
Table 1. Approximate MMS LD50 for Aag transgenic mice.
Mouse Strain MMS LD50
C57Bl/6 150 mg/kg
Aag2/2 150 mg/kg
AagTg Fo 8756* 150 mg/kg
AagTg Fo 943* 120 mg/kg
AagTg Fo 243* 80 mg/kg
*Indicates that the Aag transgene is expressed in an Aag2/2 background.
doi:10.1371/journal.pgen.1003413.t001
Table 2. Approximate LD50 of Aag
2/2 and Aag transgenic
mice to various genotoxic agents.
Approximate LD50
Mouse Strain MMS MNU AOM MMC CAA
C57Bl/6 150 mg/kg 118 mg/kg 28 mg/kg 9 mg/kg 15.2 mg/kg
Aag2/2 150 mg/kg 118 mg/kg 28 mg/kg 9 mg/kg 15.2 mg/kg
AagTg Fo 243* 80 mg/kg 35 mg/kg 18 mg/kg 9 mg/kg 15.2 mg/kg
MMS, Methyl methanesulfonate; MNU, N-methyl-N-nitrosourea; AOM,
Azoxymethane; MMC, Mitomycin C; CAA, Chloroacetaldehyde.
*Indicates that the Aag transgene is expressed in an Aag2/2 background.
doi:10.1371/journal.pgen.1003413.t002
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treatment (150 mg/kg). Because massive cell death was observed
in rapidly-proliferating tissues including the spleen, thymus, and
bone marrow (BM) for all genotypes, we reduced the MMS dose to
75 mg/kg to better discern any differences in sensitivity in these
tissues. Even with this reduced MMS dose, AagTg mice displayed
evidence of whole-body toxicity whereas WT and Aag2/2 mice did
not. Remarkably, as early as 24 h following MMS treatment,
AagTg mice exhibit greater reductions in body weight than WT or
Aag2/2 mice (Figure 3A), losing .10% of their BW by 24 h; the
decreased body weight remains significantly greater than that for
WT and Aag2/2 mice for over 3 weeks (Figure 3B). Moreover,
24 h following MMS treatment (75 mg/kg), we observe gross
tissue atrophy in the thymus and spleen in AagTg mice; AagTg mice
exhibit 46% and 53% decreases in thymus and spleen weight,
respectively, compared to untreated tissues (Figure 3C). WT mice
also exhibit a slight (26%) but significant decrease in spleen weight
following MMS treatment but no evidence of thymic atrophy
(compared to untreated WT mice). Strikingly, Aag2/2 mice are
completely protected from the MMS-induced atrophy in both the
thymus and spleen (Figure 3C). Further, ex vivo clonogenic survival
assays illustrate that AagTg bone marrow (BM) cells display
dramatically increased MMS sensitivity, compared to WT and
Aag2/2 mice; as previously published, Aag2/2 BM cells are less
sensitive than WT BM cells to MMS (Figure 3D) [28]. However,
not all tissues that exhibit increased Aag activity reveal evidence of
gross tissue atrophy. Figure S2 illustrates that tissue weights of the
heart, kidney, brain, gonadal fat pad, skeletal muscle and liver
remain unchanged following MMS treatment (75 mg/kg). Finally,
Figure S3 illustrates that AagTg mice exhibit severe cell death
within the pancreatic b-islets following MMS treatment (150 mg/
kg), which is not observed in WT or Aag2/2 mice. The b-cells
exhibit nuclear fragmentation and pyknosis, a state of increased
chromatin condensation. Taken together, these results reveal that
the ,2–9 fold increase in Aag activity in the thymus, spleen, BM,
and pancreas relative to WT (Table S1) renders these tissues
dramatically more sensitive to the toxic effects of MMS. Further,
we observe increased MMS toxicity in only a subset of tissues
expressing the Aag transgene, underscoring the importance of
cellular context in determining MMS sensitivity in AagTg mice.
Unexpectedly, 24 h following a high MMS dose (150 mg/kg),
we observe cell death in the cerebellar granule cells, the cell type
which comprises 99% of the granular layer of the cerebellum.
Following MMS treatment, there is a striking change in
cerebellar morphology in AagTg mice. We observe severe
cerebellar lesions containing numerous pyknotic nuclei surround-
ed by white spaces, indicative of edema (Figure 4A). Pyknotic
nuclei, but not edema, are also observed, albeit at a lower
frequency, in the cerebella of treated WT mice, whereas the
cerebella of treated Aag2/2 mice are indistinguishable from
untreated mice (Figure 4A). The regions of edema were
quantitated using image analysis software; examples of colorized
lesions are shown in the lowest panel of Figure 4A. In untreated
mice, no edema is observed (Figure 4B). However, 24 h following
MMS (150 mg/kg), there is an obvious increase in edema in
AagTg mice compared to either WT or Aag2/2 mice, and a trend
towards an increase in WT compared to Aag2/2 mice (p = 0.308),
suggesting that Aag2/2 mice are protected against MMS-
mediated cerebellar toxicity. Here we illustrate that MMS
treatment results in severe cerebellar damage that is Aag-
dependent. Although cerebellar damage has been described
following treatment of early postnatal mice (PND3) with the
alkylating agents methylazoxymethanol and mechlorethamine, to
our knowledge, it has not previously been demonstrated following
treatment of adult mice [49,50].
Aag-dependent, MMS-induced cerebellar degeneration
results in impaired motor function
Given the importance of the cerebellum in coordinating motor
function, we investigated whether MMS-induced cerebellar lesions
result in diminished motor control. Decreased mobility was
observed in all genotypes following a high MMS dose (150 mg/
kg) (data not shown), so we reduced the MMS dose (90 mg/kg) for
gait comparisons between WT, Aag2/2, and AagTg mice. The gait
of all genotypes was indistinguishable under untreated conditions
(Figure S4). However, three hours following MMS treatment, the
gait of WT and Aag2/2 mice is unchanged whereas AagTg mice
exhibit severe gait abnormalities including immobility, circling,
and walking backwards (Figure 5A). We quantitated motor defects
by performing an accelerating speed rotarod test. To ensure all
genotypes were capable of performing for .30 seconds on the
rotarod test, we further reduced the MMS dose (60 mg/kg).
Without MMS exposure, all genotypes performed comparably
(Figure 5B). However, three hours following MMS treatment, we
observed a dramatic decrease in rotarod performance for AagTg
mice compared to WT and Aag2/2 mice (Figure 5B). Although the
AagTg mice slightly improved their performance by 4 hours, it
remained significantly decreased compared to WT and Aag2/2
mice (Figure 5B). Treated WT and Aag2/2 mice performed
similarly to untreated mice, indicating that MMS at this dose
(60 mg/kg) caused no motor dysfunction in WT or Aag2/2 mice.
We next increased the MMS dose to one that resulted in
obviously impaired motor function in WT mice (140 mg/kg), and
again examined motor function using the rotarod test (Figure 5C);
the AagTg mice could not be included in this experiment due to
their extreme sensitivity at this MMS dose. Strikingly, even at this
high dose, Aag2/2 mice remain completely protected against
MMS-induced motor dysfunction; they not only exhibit signifi-
cantly better performance than WT mice, but their performance
following MMS remains the same as in untreated conditions
(Figure 5C). This observation is consistent with the absence of
histological cerebellar lesions in Aag2/2 mice following MMS
(150 mg/kg) treatment (Figure 4A). Together, these data under-
score the importance of BER coordination in neuronal homeo-
stasis; MMS induces cerebellar degeneration that is exacerbated
by imbalanced BER in AagTg mice. Perhaps most importantly, the
elimination of BER initiation in Aag2/2 mice completely
suppresses MMS-induced cerebellar toxicity.
The absence of Parp1 suppresses Aag-dependent MMS-
induced toxicity in several tissues
Given the role for Parp1 in mediating alkylation toxicity, we
next set out to determine whether eliminating Parp1 could
modulate the MMS-induced cytotoxicity observed in WT and
AagTg mice; to explore this possibility, we utilized Parp12/2 mice
[51]. We first investigated MMS-induced retinal degeneration
(RD). As previously illustrated, MMS induces the selective
degeneration of the photoreceptors in the retinal outer nuclear
layer (ONL) in WT mice, whereas juxtaposed retinal layers are
unaffected [29]. While Aag2/2 mice are completely protected from
such RD, AagTg mice are hypersensitive compared to WT and
Aag2/2 mice, as observed by decreased number of cells found
within the ONL (Figure 6 and [29]). Strikingly, we observe that
Parp12/2 mice are also completely protected against MMS-
induced RD (Figure 6). Moreover, MMS-induced RD is
completely abrogated in AagTg/Parp12/2 mice, indicating that
Parp1 deficiency completely suppresses the Aag-dependent MMS-
hypersensitivity in photoreceptors of AagTg mice (Figure 6). To
confirm that Parp1 enzymatic activity is stimulated during MMS-
Aag and Parp1 Confer Alkylation Sensitivity in Mice
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induced Aag-dependent RD, we evaluated Parp1 activation by
immunodetection of the PAR polymer. Figure S5 shows that
increased PAR polymer staining is observed 24 h following MMS
treatment, in an Aag-dependent manner, confirming that MMS-
induced RD is preceded by Parp1 activation. Similarly, we observe
that Parp1 deficiency is able to suppress the pancreatic b-cell death
observed in AagTg mice following an acute MMS treatment
(Figure S6). Together, these data indicate that the BER
intermediates exert their toxicity through the hyperactivation of
Parp1. Further, we find that deletion of Parp1 prevents MMS-
induced toxicity and that both Aag and Parp1 are required for
MMS-induced cell death.
We next investigated the requirement for Parp1 in MMS-
induced cerebellar degeneration. While MMS (150 mg/kg)
induces severe cerebellar lesions in AagTg mice (Figure 4A), Parp1
deficiency completely suppresses this Aag-dependent, alkylation-
induced cerebellar toxicity (Figure 7A). Image analysis confirms
that the drastic increase in the edema in MMS-treated AagTg mice
was completely abrogated in AagTg/Parp12/2 mice (Figure 7B).
Consistent with rescue of cerebellar lesions in AagTg/Parp12/2
mice (Figure 7B), we illustrate using gait analysis that Parp1
deficiency prevents the motor dysfunction observed following
MMS treatment in AagTg mice (Figure S7). Additionally, rotarod
assays were performed in WT, AagTg and AagTg/Parp2/2 mice to
quantitate motor function. Following MMS (60 mg/kg), the motor
function in WT mice remain unaffected, whereas AagTg mice
exhibit significantly diminished performance (Figure 7C). Impor-
tantly, following MMS, AagTg/Parp12/2 mice perform just as well
as WT mice, indicating that the Aag-dependent MMS-hypersen-
sitivity in the cerebella of AagTg mice is completely dependent on
Parp1 (Figure 7C). Further, the Parp1 deficiency was sufficient to
prevent the motor dysfunction observed at high MMS doses. As
described above, at high MMS (140 mg/kg), WT mice exhibit
severe motor dysfunction (Figure 5C and Figure 7D); however we
find that like Aag2/2 mice, Parp12/2 mice are protected against
MMS-induced motor dysfunction and exhibit enhanced rotarod
Figure 3. AagTgmice are more susceptible to MMS-induced toxicity. (A) Body weight (BW) of WT (n = 14), Aag2/2 (n = 12) and AagTg (n = 12)
mice 24 h following MMS treatment (75 mg/kg). Representative data (mean 6 standard deviation) from 3 independent experiments are shown. (B)
BW is illustrated for WT (n = 14), Aag2/2 (n = 12) and AagTg (n = 9) mice following MMS treatment (75 mg/kg). Data represent mean 6 standard
deviation. (C) Tissue weights of spleen and thymus are illustrated for n.6 per genotype. Striped bars represent untreated tissue weights and solid
bars represent tissue weights 24 h following MMS treatment (75 mg/kg). Percent decrease in tissue weight observed following MMS treatment is
shown above bars. Data represent mean6 SEM. (D) Ex vivo bone marrow (BM) clonogenic survival assays were performed using BM isolated from WT
(n = 3), Aag2/2 (n = 3) and AagTg (n = 3). Data represent mean 6 SEM. All the mice used in this figure are males on a pure C57BL/6 background.
doi:10.1371/journal.pgen.1003413.g003
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Figure 4. MMS induces severe cerebellar lesions AagTg mice. (A) H&E stained image of cerebellar granule cells from WT, Aag2/2 and AagTg
mice either in untreated conditions or 24 h following MMS treatment (150 mg/kg). Representative images are shown of n.6 experiments. Yellow
arrows indicate pyknotic nuclei. Scale bar is 100 mm on low magnification images (black bar) and 15 mm on high-magnification images (white bar).
Aag and Parp1 Confer Alkylation Sensitivity in Mice
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performance compared to MMS-treated WT mice (Figure 7D).
The mice in this experiment are on a mixed C57Bl/6:129S6
background, and the slight decrease in rotarod performance
observed here, compared to Figure 5, can be attributed to
differences in genetic background, as previously shown [52,53].
Together, these data (Figure 6, Figure 7, and Figure S6) indicate
that both Aag and Parp1 are required for the severe MMS-
mediated cytotoxicity observed in retinal photoreceptors, pancre-
atic b-cells, and cerebellar granule cells.
Discussion
Using AagTg mice, we have investigated the in vivo consequences
of imbalanced BER. Although increased human AAG activity was
recently linked to elevated lung cancer risk [7,9] and decreased
survival of glioma patients [54,55], increased Aag activity in mice
does not affect spontaneous tumorigenesis or overall longevity.
However, dramatic in vivo consequences of imbalanced BER were
revealed upon treating AagTg mice with alkylating agents. AagTg
mice exhibited increased whole-animal lethality to both SN1 and
SN2 methylating agents, but not to other genotoxic agents. Our
data suggest that under basal conditions, the level of BER
intermediates produced during the repair of spontaneous DNA
damage is readily accommodated by the downstream BER
enzymes. However, in the presence of higher levels of DNA base
damage generated by alkylating agents, Aag initiates BER at a rate
such that downstream BER enzymes may be unable to efficiently
process the toxic BER intermediates, resulting in cell death and
tissue damage, and potentially in the death of the animal (Figure 1).
Therefore, it may be predicted that patients exhibiting increased
AAG activity may exhibit increased sensitivity or more detrimental
side-effects to alkylating chemotherapeutic agents. Indeed, AAG
expression does predict temozolomide sensitivity in glioblastoma
and ovarian cancer cell lines [48,56], and AAG expression
inversely correlates with survival of glioma patients following
treatment [54]. Together, the data presented here as well as
published findings provide justification for an epidemiological
study examining alkylation sensitivity in correlation with AAG
activity levels.
Imbalanced BER in AagTg mice confers increased MMS
sensitivity to cells in the thymus, spleen, bone marrow, retina,
pancreas, and cerebellum. Further, Aag activity predicts MMS
toxicity in vivo, such that relative sensitivities are as follows:
AagTg.WT.Aag2/2. However, Aag activity is not the sole
determinant of MMS-mediated tissue cytotoxicity; numerous
tissues in the AagTg mice exhibit ,5–8 fold increases in Aag
activity (e.g. heart, kidney, liver) but show no evidence of increased
MMS sensitivity (Figure S2 and data not shown), underscoring the
importance of cellular context in determining Aag-mediated
alkylation sensitivity. It remains to be determined why only
subsets of cell types are susceptible to Aag-mediated alkylation
toxicity. In the highly-proliferative thymus, spleen, and bone
marrow, unrepaired BER intermediates presumably result in
replication fork collapse and DSBs, thus triggering cell death.
However, pancreatic b-cells are not highly-proliferative and both
the adult cerebellar granule cells and retinal photoreceptor cells
are non-replicating, post-mitotic tissues [57], indicating cell death
must be replication-independent. It is important to note that even
within tissues exhibiting MMS sensitivity, toxicity is not uniform
across all cell types in the tissue. For example, only the ONL of the
retina undergoes MMS-induced degeneration whereas the juxta-
posed retinal layers remain intact. Similarly, following MMS
treatment, cerebellar purkinje cells remain unaffected while
neighboring cerebellar granule cells are ablated. Why are some
cells so sensitive, whereas others are resistant? The activity of
downstream BER proteins in the sensitive cells may simply be
insufficient to process accumulating BER intermediates; this and
other possibilities are currently under investigation. Together, our
data emphasize the concept that BER imbalance and the resulting
intermediates can profoundly affect cellular and tissue homeosta-
sis, and reveal that in certain contexts, the absence of DNA repair
can actually be beneficial to an organism.
Insets contain magnified images of area in dashed boxes. (B) Quantitation of cerebellar phenotype was performed on images from WT (n= 4), Aag2/2
(n = 3) and AagTgmice (n = 4). Representative images with identified objects (edema) colorized for visualization. Greater than 3 images/cerebella were
quantitated per mouse, and the average sum of object area per image is presented. Data represent mean 6 SEM. All the mice in this figure are on a
pure C57BL/6 background.
doi:10.1371/journal.pgen.1003413.g004
Figure 5. MMS induces an Aag-dependent decrease in motor function. (A) Representations of gait are shown for WT (n = 3), Aag2/2 (n = 3)
and AagTg (n = 3) mice three hours following MMS treatment (90 mg/kg). (B) Rotarod performance is shown for WT (n = 18), Aag2/2 (n = 17) and
AagTg (n = 25) mice under untreated conditions and following MMS treatment (60 mg/kg). Data represent mean 6 SEM. (C) Performance for the
rotarod challenge is shown for WT (n = 17) and Aag2/2 (n = 22), 3 and 4 h following MMS treatment (140 mg/kg). Data represent mean6 SEM. All the
mice in this figure are on a pure C57BL/6 background.
doi:10.1371/journal.pgen.1003413.g005
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Although it has been known for 30 years that Parp inhibition
potentiates alkylation-induced toxicity [58], the recent discovery of
synthetic lethality in BRCA1/2 homologous recombination-
deficient tumors upon Parp inhibition has renewed intense interest
in using PARP inhibitors for cancer chemotherapy [59,60].
However, in stark contrast to this well-documented potentiation
of alkylation toxicity by Parp inhibitors [30,61], we observe
complete suppression of alkylation toxicity by genetic deletion of
Parp1. This is likely due to multiple inherent differences between
Parp1 deficiency and Parp inhibition [62]. The main difference is
the proposed trapping of Parp1 on DNA substrates by Parp
inhibitors, which thereby prevents BER and interferes with
replication [63,64]. Although this ‘DNA trapping’ phenomenon
has been demonstrated for many Parp inhibitors, it may not be the
case for all Parp inhibitors [64–67]. In fact, uncovering the
relationship between the inhibition of the catalytic activity of Parp,
the potency of DNA trapping, and overall toxicity by Parp
inhibitors has recently garnered interest [66]. Another difference
between Parp1 deficiency and Parp inhibition resides in the fact
that Parp inhibitors are not specific for the inhibition of Parp1, but
can potentially inhibit the catalytic activity of 17 other members of
the Parp superfamily [68]. Regardless of the differences between
Parp1 deletion and Parp inhibition, suppression of alkylation
toxicity upon treatment of cultured cells with Parp inhibitors is not
unprecedented [43,69–71].
Although Parp1 deficiency mechanistically differs from Parp
inhibition, it was surprising to observe that Parp1 deficiency was
capable of completely suppressing MMS hypersensitivity in
numerous tissues under conditions of imbalanced BER (AagTg
mice). This in vivo data reveals that Parp1 acts downstream of Aag
to govern alkylation sensitivity, presumably through Parp1’s
alternate function in mediating programmed necrosis (Figure 1B)
[12,71]. Interestingly, interrupting Parp1’s function has been
shown to be protective in several other models of neuronal damage
including ischemia/reperfusion and glutamate excitotoxity [72–
74], and retinal degeneration induced by ischemia/reperfusion or
by treatment with PDE6 inhibitor, which mimics the rd1 mutation
[75,76]. Whether Aag also plays a role upstream from Parp1 in
these modes of tissue damage remains to be determined.
Using genetic experiments, we show here that modestly
increased Aag activity results in dramatic increases in tissue and
whole-animal sensitivity to alkylating agents. Given that human
AAG activity varies greatly among healthy individuals (Figure 2),
and also that BER protein levels are known to be altered in
numerous human cancers [77–79], the resulting imbalanced BER
may have dramatic consequences in patients undergoing chemo-
therapy involving alkylating agents [6]. Moreover, PARP1
expression and activity varies greatly in human tumors [80], and
SNPs in PARP1 have been associated with numerous cancers [81–
83]. We illustrate that Parp1 deficiency protects against alkylation
sensitivity at both the tissue and whole-animal level. Therefore,
decreased PARP1 activity may result in a decreased response
during a chemotherapeutic regimen. Indeed, leukemic patients
expressing decreased PARP1 levels exhibit resistance to standard
chemotherapy therapy [84,85]. Taken together, our findings
illustrate that monitoring for both BER imbalance and PARP1
expression is warranted prior to selecting a chemotherapeutic
regimen that includes alkylating agents.
Materials and Methods
Ethics statement
The MIT Committee on the Use of Humans as Experimental
Subjects reviewed and approved the research involving human
subjects. Written informed consent was obtained from all
participants. All animal procedures were approved by the MIT
Committee on Animal Care.
Animals
Aag2/2 and Aag transgenic (AagTg) mice were described
previously [21,29]. Parp 2/2 mice (Jackson Laboratories) were
described previously [51]. Mice were fed a standard diet ad libitum,
Figure 6. Parp1 deficiency protects against Aag-dependent, MMS-induced toxicity in retina photoreceptors. H&E stained retinal
sections for WT, Aag2/2, Parp12/2, AagTg, and AagTg/Parp12/2 under untreated conditions or 7 d following MMS treatment (75 mg/kg). Scale bar is
15 mm. Representative images for n = 5 mice/genotype are shown. All the mice used in this figure are mixed C57BL/6:129S background. ONL, Outer
nuclear layer; INL, inner nuclear layer.
doi:10.1371/journal.pgen.1003413.g006
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Figure 7. Parp1 deficiency protects against Aag-dependent, MMS-induced motor dysfunction. (A) H&E stained cerebellar sections are
shown from WT, Aag2/2, Parp12/2, AagTg, and AagTg/Parp12/2 under untreated conditions or 24 h following MMS treatment (150 mg/kg). Scale bar
is 15 mm. Representative images for n = 5 mice/genotype are shown. (B) Quantitation of cerebellar phenotype is shown. Three or more images/
cerebella were quantitated per mouse, and 3 mice per genotype analyzed for quantitation; the average sum of object area (edema) per image is
presented. (C) Performance during the rotarod challenge in WT (n = 15), AagTg (n = 18), and AagTg/Parp12/2 (n = 9) is illustrated under untreated
conditions and following MMS treatment (60 mg/kg). (D) Performance for the rotarod challenge is shown for WT (n = 8), Aag2/2 (n = 11), and Parp12/
2 (n = 15) mice four hours following MMS treatment (140 mg/kg). All the mice used in this figure are mixed C57BL/6:129S background. All data
represent mean 6 SEM.
doi:10.1371/journal.pgen.1003413.g007
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housed in an AAALAC-accredited facility, and euthanized by
CO2 asphyxiation. Additional details about the mice utilized are
included in the Methods S1.
Reagents
Methyl methanesulfonate (MMS), chloroacetaldehyde (CAA),
N-methyl-N-nitrosurea (MNU), and Mitomycin C (MMC) were
obtained from Sigma (St. Louis, MO). Azoxymethane (AOM) was
obtained from the Midwest Research Institute, NCI Chemical
Repository.
Treatments
Approximate LD50 (whole-animal sensitivity to genotoxic
agents) was determined as in Deichmann and LeBlanc [86].
Acute MMS treatments were performed by i.p. injecting mice with
varying doses of MMS (60–150 mg/kg).
Tissue processing and histopathology
Tissues were processed at the David H. Koch Institute for
Integrative Cancer Research, Histology Core Facility; they were
paraffin-embedded, sectioned at 5 mm, and stained with hema-
toxylin and eosin (H&E). All H&E stained slides were blindly
analyzed by a pathologist (R.T.B) for the cause of death as well as
for the identification of any tumors/lesions.
Image quantitation
Volocity (Perkin Elmer) image analysis software was used to
quantitate edema, as observed by white spaces in cerebellar
histological sections. Thresholding was performed using the Red/
Green/Blue quantitation tool and objects smaller than 5 microns
were excluded. The sum of all object areas/image was calculated
and greater than 3 representative images were analyzed for each of
3 animals.
Ex vivo bone marrow clonogenic assays
Bone marrow cells were harvested from the femurs of 6–12
weeks old WT, Aag2/2 and AagTg mice. Cells were treated with
varying dose of MMS, washed, resuspended in complete media
mixed with methylcellulose (Stem Cell Technologies), plated in
duplicate and the percent survival calculated as in [28].
Experiments were performed in triplicate.
Evaluation of Aag activity in mouse tissues
Cell extracts were made from tissues harvested from WT,
AagTg, and Aag2/2 mice. Tissues were sonicated in Aag
glycosylase assay buffer (20 mM Tris-Cl pH 7.6, 100 mM KCl,
5 mM EDTA, 1 mM EGTA and 5 mM b-mercaptoethanol) with
protease inhibitors. Protein concentration was measured using
micro BCA Kit (Pierce). Glycosylase assays were performed as
previously published [21]. A [32P]c-labeled double-stranded
25mer oligonucleotide containing a single centrally located
hypoxanthine residue [59-GCAATCTAGCTTTTT(Hx)C-
GATGTATGC-39] was incubated with an amount of extract
determined to be in the linear range for activity at 37uC for 1 h.
The resulting AP sites were cleaved by incubation with 0.1 N
NaOH at 70 uC for 20 min. A phosphorimager was used to
visualize and quantitate Aag DNA glycosylase activity.
Evaluation of AAG activity in PBMC
Peripheral blood samples were obtained from healthy individual
at the MIT Catalyst Clinical Research Center, and PBMC were
isolated using standard Ficoll-Paque (Sigma) density gradient
centrifugations. The glycosylase assay was performed as above
with the following exceptions; the [32P]c-labeled lesion-containing
oligonucleotide used was 59-GCAATCTAGCCA(eA)GTC-
GATGTATGC-39, and the glycosylase reaction was incubated
for 37uC for 2 h.
Evaluation of motor function
To capture gait abnormalities, the mouse hind paws were
dipped into non-toxic paint; mice were placed in a closed
container on a sheet of white paper and allowed to walk freely.
The Ugo Basile 7650 Accelerating Rotarod was used to evaluate
fore-limb and hind-limb motor coordination. The rotarod testing
protocol was two weeks long; the first week examined motor
function under untreated conditions and the second week
following MMS-treatment. An accelerating speed rotarod protocol
was used, which linearly accelerates the rotating rod from 4 to
40 RPM in 10 minutes. During each week, day 1 to 4 consisted of
training the mice for two 5-minute runs to familiarize the mice
with the apparatus. On day 5, the mice underwent two tests, with
an hour rest between the tests; the time spent on the rotatod is
recorded as a measurement of performance. The 2nd week follows
the same schedule, 4 days training and test on the fifth day.
However, on the 5th day of the second week, the mice were treated
with either 60 or 140 mg/kg MMS by i.p. injection and the test
performed 3 and 4–4.5 hours post-treatment.
Immunofluorescence
5 mm unstained sections were deparaffinized and rehydrated in
a graded ethanol series, incubated in citrate buffer and thermally
processed for epitope retrieval. Sections were permeabilized three
times (5 minutes) with PBS-T (16PBS+0.1% Triton X-100). Non-
specific antibody binding sites were blocked by incubating sections
with 16 PBS-T+heat-inactivated goat serum (HIGS; 10%) for
30 minutes. Sections were then incubated with primary anti-PAR
antibody (1:250; BD Pharmingen) for 2 hours at RT. After 5
washes in PBS-T, sections were incubated for 30 min with
secondary antibody DyLight 488 (1:1000; Vector Labs). Nuclear
counterstaining was done using TOPRO-3 (Invitrogen). All
staining was performed in humidified chambers. A Zeiss Axiovert
LSM 510 META confocal microscope (Germany) with a 636 oil
objective was used to image the retinal sections. Images were
viewed and analyzed using LSM Image Browser.
Statistics
Statistical analyses were performed using GraphPad Prism
software. Data are presented as mean 6 SEM or mean 6 SD (as
stated in figure legends). Statistical significance was determined
using unpaired t-test or two-way ANOVA. Kaplan-Meier survival
curves were generated and survival differences determined using
the Log-Rank test. A p-value is considered significant if less than
0.05.
Supporting Information
Figure S1 Evaluation of AagTg mice. (A) Aag activity is
illustrated for a panel of tissues in WT, Aag2/2 and AagTg mice.
In vitro glycosylase assays were performed on tissues isolated from
n = 3 animals. (B) Kaplan Meier Survival curves are shown for an
aging cohort of WT (n = 19), Aag2/2 (n = 27) and AagTg (n = 26)
mice.
(TIF)
Figure S2 Aag transgene expression does not result in MMS
atrophy in all tissues. Tissue weights of the heart, left kidney, brain,
left gonadal fat pad, and left gastrocnemius/soleus skeletal muscles
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were taken in untreated and 24 h post MMS treatment (75 mg/
kg). The mice utilized in this experiment were age-matched males
on a pure C57Bl/6 background.
(TIF)
Figure S3 MMS induces pancreatic b-cell death AagTg mice.
H&E stained slides of pancreatic b-islets (outlined in yellow) from
WT, Aag2/2 and AagTg mice either in untreated conditions or
24 h following MMS treatment (150 mg/kg). Untreated sections
show healthy pancreatic histology. Following MMS treatment,
only AagTg exhibit evidence of toxicity within the b-cells, as
illustrated by pyknotic and fragmented nuclei (shown by yellow
arrows). Very few intact nuclei are observed in the pancreatic b-
islet of the MMS-treated AagTg mice (green arrows). Representa-
tive images are shown of n.3 experiments. Scale bar is 12 mm.
(TIF)
Figure S4 Untreated mice exhibit similar gait. Representations
of gait are shown for WT (n = 3), Aag2/2 (n = 3), and AagTg (n = 3)
mice prior to MMS treatment.
(TIF)
Figure S5 Aag-dependent Parp1 activation is observed in the
retinal outer nuclear layer (ONL) following MMS treatment.
Immunofluorescence staining with a-PAR antibody and TOPRO
nuclear counterstain was performed on retinal sections from WT,
Aag2/2 and AagTg mice 24 h following MMS (75 mg/kg)
treatment. ONL, outer nuclear layer; INL, inner nuclear layer.
(TIF)
Figure S6 Parp1 deficiency protects against alkylation-induced
pancreatic b-cell death AagTg mice. H&E stained slides of
pancreatic b-islets from WT, Aag2/2, Parp12/2, AagTg, and
AagTg/Parp12/2 mice either in untreated conditions or 24 h
following MMS treatment (150 mg/kg). Representative images
are shown of n.2 experiments. The pancreatic b-islets are
centered in image and surrounded by pancreatic acinar cells.
Untreated sections show healthy pancreatic histology. Following
MMS treatment, only AagTg exhibit evidence of pancreatic b-cell
toxicity, as illustrated by pyknotic and fragmented nuclei (yellow
arrow). Very few intact nuclei are observed in the pancreatic b-
islet of the MMS-treated AagTg mice (green arrows). Magnification
is 606; scale bar is 16 mm.
(TIF)
Figure S7 Parp1 deficiency protects against alkylation-induced
gait abnormalities. Representations of gait are shown for WT
(n = 3), Parp12/2 (n = 2), AagTg (n = 3) and AagTg/Parp12/2 (n = 2)
mice shown three hours following MMS treatment (90 mg/kg).
(TIF)
Methods S1 Supplemental Materials and Methods.
(DOCX)
Table S1 Aag activity in Aag transgenic founder lines.
(DOCX)
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